SEC Company Response from VOLITIONRX LTD (VNRX) (CIK 0000093314) (VNRX) — Feb 13, 2020
VOLITIONRX LTD (VNRX) (CIK 0000093314)
Date: Feb. 13, 2020 · CIK: 0000093314 · Accession: 0001078782-20-000104
AI Filing Summary & Sentiment
File numbers found in text: 333-236335
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request Letter VOLITIONRX LIMITED 13215 Bee Cave Parkway Suite 125, Galleria Oaks B Austin, Texas 78738 February 13, 2020 SUBMITTED VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: William Mastrianna Re:VolitionRx Limited Acceleration Request Registration Statement on Form S-3 File No. 333-236335 Requested Date:February 14, 2020 Requested Time:5:00 P.M. Eastern Time Dear Mr. Mastrianna: Pursuant to Rule 461 of the Securities Act of 1933, as amended (the “Securities Act”), VolitionRx Limited, a Delaware corporation (the “Company”), hereby respectfully requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above, or as soon thereafter as practicable. Should the Commission have any questions regarding this acceleration request, please do not hesitate to contact Marc G. Alcser, an attorney with the Company’s outside legal counsel, Stradling Yocca Carlson & Rauth, P.C., via telephone at (949) 725-4136 or via email at malcser@sycr.com. Sincerely, VOLITIONRX LIMITED /s/ Cameron Reynolds Cameron Reynolds President and Chief Executive Officer cc: Stradling Yocca Carlson & Rauth, P.C. Marc G. Alcser, Esq.